01 June 2012 | News | By BioSpectrum Bureau
Temptime expands business in Asia
A business office in Beijing is a significant advancement in effort to improve distribution of temperature-sensitive pharmaceutical products in and around Asia
Singapore: Temptime, the world leader in time temperature indicators, has opened a business office in Beijing, China, marking a significant advancement in their global effort to improve distribution of temperature-sensitive pharmaceutical products in and around the Asian region.
"There is a significant opportunity to preserve the quality and safety of pharmaceutical medicines used in, and exported from, this growing market in Asia," explained Mr Reenat Van den Hooff, president, Temptime. "Our decision to open a business office in Beijing is another step in realizing our strategy to improve global health by bringing innovative cold chain management solutions to the worldwide healthcare community."
With the addition of the Beijing office, Temptime global presence now includes dedicated business development operations and/or agents in Japan, China, India, the United Arab Emirates and Argentina. The company's worldwide headquarters are in Morris Plains, NJ.
Mr Van den Hooff also announced the appointment of Mr Hui (Leo) Wang as director of business development, Asia. "Mr Wang has extensive experience in vaccines, commercial distribution, supply chain logistics and cold chain management, having served in various senior supply chain positions for several global life science companies such as Sanofi Pasteur, Pfizer/Wyeth, and Johnson & Johnson," he explained. "He will be an asset to Temptime as we expand our global presence - and our robust product offering - to meet the growing medical need for innovative and cost-effective cold chain solutions in this important region," he said.
"I am looking forward to helping support Temptime's business growth in China by facilitating uptake and implementation of Temptime's reliable, cost-effective temperature monitoring technologies for vaccines and biotech products," said Mr Wang.